Arrhythmias & electrophysiology
Right ventricular function is a predictor for sustained ventricular tachycardia requiring anti-tachycardic pacing in arrhythmogenic ventricular cardiomyopathy: insight into transvenous vs. subcutaneous implantable cardioverter defibrillator insertion
Authors' conclusion
VA event rates are high in ARVC patients with a majority having VT falling in the VF zone resulting in ICD shock(s).
Study context
- Population
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) patients with ICDs20 (43.5%) secondary prevention
- Participants
- 46 patients
- Outcome
- VA events during follow-up, by device therapy, and their predictors
Methodological detailssingle-centre, prospectively collated registry data
- Single-centre
- Prospectively collated registry data
Main finding
As reported in the abstract
VA events · follow-up 12.1 ± 6.9 years
- Patients with VA events
- 31 (67.4%)
- Ventricular fibrillation (VF)
- n = 2, 6.5%
- VT in VF zone resulting in ICD shock(s)
- n = 14], 45.2%
- VT resulting in anti-tachycardia pacing (ATP)
- n = 10, 32.3%
- Both VT resulting in ATP and ICD shock(s)
- n = 5, 16.1%
- Severely impaired right ventricular (RV) function as independent predictor of VT resulting in ATP, HR
- 16.80 (3.74-75.2); P < 0.001 (95% CI)
- Predictive accuracy, AUC
- 0.88 (0.76-1.00); P < 0.001 (95% CI)
Observational data: associations, not effects.
Further findings
ATP success
- ATP successful
- 34.5%
Safety
- Lead failure rate
- 11/46, 23.9%
Original publication
Right ventricular function is a predictor for sustained ventricular tachycardia requiring anti-tachycardic pacing in arrhythmogenic ventricular cardiomyopathy: insight into transvenous vs. subcutaneous implantable cardioverter defibrillator insertion. Europace. Published 22 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →